Edition #9: The Reversal Idea Just Entered a Human
A gene therapy built to return old cells to a younger state started its first human trial in June 2026.
Most people ask the same thing about aging. Whether it can be reversed. Whether a cell that lost function over decades can be brought back to the state it had before those decades did their work.
For most of biotech history that question lived in theory. In June it entered a person.
The Signal
Aging shows up first as a control problem inside the cell. Every cell carries a layer of settings that decide which genes stay on and which stay off. That layer is the epigenome. When a cell is young, those settings sit in one pattern. Over the years they drift, and as they drift the cell does its job worse. Much of what we feel as getting older is that drift.
One way to fix the drift is to reset a cell all the way back to a blank, stem-like state. That works in a dish and it carries a hard problem. A cell reset that far stops being what it was, and it can turn into a tumor. Too far to put in a body.
Partial reprogramming rolls the settings only part of the way back. Far enough to recover younger function, not so far that the cell loses its identity. A retinal cell stays a retinal cell. It just works closer to how it worked years earlier.
On June 9, 2026, Life Biosciences dosed the first human with a therapy called ER-100. It uses controlled amounts of three of the molecular signals that reset a cell’s gene activity toward a younger pattern, delivered to the retinal ganglion cells, the cells whose fibers form the optic nerve and carry sight to the brain. The target is optic neuropathy, conditions like open-angle glaucoma where those cells lose function and vision goes with them. The trial is Phase 1. It is built to test whether the therapy is safe at a given dose, with early measures of vision alongside.
ER-100 goes at the mechanism itself, the aged state of the cell. That is why a Phase 1 in the eye is worth the attention of people who do not work in biotech.
I have watched several technology waves arrive over 25 years. Each one looked like a lab curiosity in the window right before it became infrastructure. This has the same shape. It is one therapy, in one tissue, at the safety stage. And the idea of returning a cell to a younger state stopped being a slide in a longevity deck and became something running inside a living person.
The 20-year horizon everyone used for “diseases of aging become treatable” is getting shorter. This is the year it moved.
The Application
Three programs show where this is real right now.
Life Biosciences, ER-100. On June 9, 2026, Life Biosciences dosed the first human with ER-100. It is the first time a partial reprogramming therapy has been put into a person. The therapy uses controlled expression of three transcription factors, delivered to retinal ganglion cells, to treat optic neuropathies including open-angle glaucoma and NAION. Phase 1, safety and tolerability, with early measures of vision.
Barabási lab network-medicine screen, Nature Aging. On June 26, 2026, a team at Northeastern and Harvard’s Brigham and Women’s, lead author Bnaya Gross, published a method that maps 2,358 genes linked to longevity and scores 6,442 approved and experimental drugs for which ones push a cell’s activity back toward a younger pattern. Starting from drugs that already cleared safety moves the slow, expensive part from finding a candidate to proving it works. Barabási was direct about the limit: it does not cure aging and it does not prove any drug extends life. It points to candidates worth testing, nothing tested yet.
AI-designed drugs. AI-designed molecules are clearing Phase 1 at 80 to 90 percent, well above the historical average near 50 percent, per a BCG analysis in Drug Discovery Today. Read the number with care. It rests on a small sample and it only measures safety. In Phase 2, where a drug has to work, AI-designed molecules succeed around 40 percent of the time, the same as everything else, and none has been approved yet. With AI, the discovery step got faster. Validation did not.
The Noise
The headlines will say we can reverse aging now. Read the stage before you believe them. ER-100 is one therapy, in one tissue inside the eye, in a Phase 1 trial. Phase 1 checks one thing, whether the treatment is safe at a given dose. It does not show the therapy works, and it does not show it carries to the rest of the body. The reprogramming milestone is real and worth your attention. Turning it into “aging is solved” skips years of trials that have not happened. Anyone selling reversal today is selling a headline the data cannot carry.
The Question
A large share of healthcare revenue comes from managing chronic conditions year after year. If a single therapy restores function that age took away, which of your revenue lines depends on that decline continuing?
Now What?
Name the revenue that assumes decline stays. Find the parts of your model that earn money from conditions being managed over years. If a one-time therapy can end some of them, you want that list before your competitors build it.
Ask your actuary the one-dose question. Single-dose therapies that replace lifelong treatment break the annual-cost model insurers and benefit plans run on. Ask how a high-cost one-time cure changes reserves against decades of managed care.
Track the trials by tissue. The signal is which tissues move next after the optic nerve, and whether a Phase 1 reads out safe. Judge progress by stage and tissue, and you will see it before the coverage does.
Ask your R&D lead what changes when discovery stops being the bottleneck. If finding a candidate gets cheap and fast, your advantage moves to how quickly and cleanly you can run validation. Most pipelines are not built for that shift yet.
What I’m Watching
The network-medicine candidates. Which of the drugs the Barabási screen flagged actually enter experimental validation, and how they perform. It is a method today, not a deployment.
Casgevy for young children. On July 1, 2026, the FDA cleared the CRISPR therapy Casgevy for children as young as 2 with sickle cell disease or transfusion-dependent beta thalassemia, adding about 5,500 eligible patients in the US. It is a one-time treatment. Gene medicine is reaching younger and broader groups faster than reimbursement systems are adjusting.
Reprogramming beyond the eye. Whether the ER-100 approach moves from the optic nerve into other tissues in follow-on trials. That is the step that would take it from a narrow win to a general one.
This is the Javier D’Ovidio Newsletter. Emerging tech without the hype. Real signals for strategic decisions.
If this edition helped you see something you were not seeing before, forward it to one leader who needs to be in the conversation.
How I make this
The judgment in this newsletter is mine. Every edition is the output of a framework I have built over 25 years in technology. I map what is happening across five forces. Then I filter signal from noise, and run each thing through one question: how does this serve life.
I use AI as a tool in that process. It helps me sweep sources across the five forces and draft. It does not decide anything. I choose the topic. I verify every figure and claim against primary sources before it goes out. I call what is signal and what is noise, and that call rests on having watched several technology waves arrive and get dismissed. I edit every edition against my own writing standards. The framework and the final call are mine, and I am accountable for every claim here.
That is the point of this newsletter. AI is a tool a person uses. The person stays responsible for what it produces.